دورية أكاديمية

[Pulmonary hypertension associated with left heart disease (group 2)].

التفاصيل البيبلوغرافية
العنوان: [Pulmonary hypertension associated with left heart disease (group 2)].
عنوان ترانسليتريتد: Pulmonale Hypertonie im Zusammenhang mit Linksherzerkrankungen (Gruppe 2).
المؤلفون: Wissmüller M, Tichelbäcker T, Finke K, Dohr J, Adler J, Ochs L, Hohmann C, Baldus S, Rosenkranz S
المصدر: Deutsche medizinische Wochenschrift (1946) [Dtsch Med Wochenschr] 2023 Nov; Vol. 148 (23), pp. 1498-1506. Date of Electronic Publication: 2023 Nov 10.
نوع المنشور: Review; English Abstract; Journal Article
اللغة: German
بيانات الدورية: Publisher: G. Thieme Country of Publication: Germany NLM ID: 0006723 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1439-4413 (Electronic) Linking ISSN: 00120472 NLM ISO Abbreviation: Dtsch Med Wochenschr Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Stuttgart [etc.] : G. Thieme, 1946-
مواضيع طبية MeSH: Hypertension, Pulmonary*/diagnosis , Hypertension, Pulmonary*/etiology , Hypertension, Pulmonary*/therapy , Heart Failure*/diagnosis , Heart Diseases*/complications, Humans ; Hemodynamics/physiology ; Prognosis
مستخلص: Patients with left heart disease (LHD) often display pulmonary hypertension (PH), which impacts morbidity and mortality. The pathophysiology of PH is complex and entails pulmonary congestion due to elevated left-sided filling pressures, pulmonary vasoconstriction as well as vascular remodeling. The recent ESC/ERS Guidelines on pulmonary hypertension updated the hemodynamic definitions of pulmonary hypertension in general, and the subclassification of post-capillary PH. This review summarizes recent advances in the diagnostic work-up and management strategies of PH associated with LHD. Specifically, we summarize revisited hemodynamic definitions and the characteristics of isolated post-capillary PH (IpcPH) and combined post- and pre-capillary PH (CpcPH). Furthermore, we review the current knowledge on the pathogenesis of PH-LHD, the prognostic relevance of hemodynamic parameters, and the management strategies, differentiating between treatment of the underlying left heart disease and therapies targeting the pulmonary circulation. The article emphasises the need for precise diagnostic work-up and individualized treatment strategies in patients with PH-LHD.
Competing Interests: MW: Vortragshonorare von Janssen; JA: Vortragshonorare von Janssen und MSD; CH: Honorare für Vorträge und/oder Beratertätigkeiten: Actelion, Bayer, MSD, Pfizer; SR: Honorare für Vorträge und/oder Beratertätigkeiten: Abbott, Acceleron, Actelion, Aerovate, Altavant, AOP Orphan, AstraZeneca, Bayer, Boehringer-Ingelheim, Edwards, Ferrer, Gossamer, Janssen, MSD, United Therapeutics, Vifor; Forschungsunterstützung an Institution: Actelion, AstraZeneca, Bayer, Janssen; JD, LO, TT und SB: keine Interessenkonflikte im Zusammenhang mit diesem Artikel.
(Thieme. All rights reserved.)
تواريخ الأحداث: Date Created: 20231110 Date Completed: 20231113 Latest Revision: 20231127
رمز التحديث: 20231128
DOI: 10.1055/a-2012-0803
PMID: 37949078
قاعدة البيانات: MEDLINE
الوصف
تدمد:1439-4413
DOI:10.1055/a-2012-0803